View source for Organization:European Society of Gene and Cell Therapy

'''European Society of Gene & Cell Therapy (ESGCT)''' formerly '''European Society of Gene Therapy (ESGT)''' is a legally registered professional body which emerged from a small [[Working group|working group]] in 1992 that focused on human [[Biology:Gene therapy|gene therapy]].
The objectives of the ESGT include the following:

* promote basic and clinical research in gene therapy;
* facilitate education (and the exchange of information and technologies) related to gene transfer and therapy;
* serve as a professional adviser to the gene therapy community and various regulatory bodies in Europe.

The official journal of the ESGT is ''The Journal of Gene Medicine''.

==Collaborations==
The ESGT works with other entities in the scientific communities in the event that an adverse effect to a specific gene therapy is discovered. Investigations the ESGT has been involved with include the adverse effects discovered during the French X-SCID gene therapy trial. The ESGT hosted a forum of 500 researchers from various facilities around the world, including representatives from the [[Organization:Stanford University|Stanford University]] and the Sloan Kettering Cancer Research Center.

==External links==
*[http://www.esgct.eu/ Official Site]
*[http://www.newswise.com/articles/view/516142/ Researchers from Israel, Southern California to Present Stem Cell Symposium]
*[http://www.telegraph.co.uk/core/Content/displayPrintable.jhtml?xml=/connected/2003/11/19/ecnfibr18.xml&site=17 Researchers team up to tackle cystic fibrosis]



{{Sourceattribution|European Society of Gene and Cell Therapy}}